1 / 16

Pertussis Update, Oregon 2012 Juventila Liko Immunization Program

Pertussis Update, Oregon 2012 Juventila Liko Immunization Program. Overview. Recent trends in pertussis, Oregon Recommended vaccination strategies . Pertussis Incidence Rates in the U.S. and Oregon, 1995–2012. Pertussis Incidence Rates by Age Group Oregon, 2000–2012.

gaenor
Télécharger la présentation

Pertussis Update, Oregon 2012 Juventila Liko Immunization Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pertussis Update, Oregon 2012JuventilaLikoImmunization Program

  2. Overview • Recent trends in pertussis, Oregon • Recommended vaccination strategies

  3. Pertussis Incidence Rates in the U.S. and Oregon, 1995–2012

  4. Pertussis Incidence Rates by Age Group Oregon, 2000–2012

  5. Incidence of Pertussis Among Persons Aged < 19 years, 2012

  6. Number of Reported Pertussis Cases by Epi Linkage and Test Type, Oregon, 2000-2012

  7. A Complicated Case of Pertussis • 8 day old baby • Mom was offered Tdap during pregnancy and declined • Conflicting history about mother’s cough onset • Days hospitalized: 3 months (PICU, ECMO and ventilator) • Siblings UTD per ALERT, mom received Tdap • Outcome?

  8. Vaccination Status of Pertussis Cases*, 2012 YTD (7/19/2012) DTaP Tdap *Closed Cases

  9. Two Exciting Projects in Oregon MAPS: • To determine the incidence and epidemiologic characteristics of B. pertussisamong all age groups. • To characterize the molecular epidemiology of circulating strains of B. pertussis. • To monitor the impact of pertussis vaccines. • To provide an infrastructure for additional special studies including those aimed at evaluating pertussis control and prevention strategies. Tdap Vaccination Strategies Evaluation ‒ To measure effectiveness of vaccination during pregnancy to prevent pertussis among infants <12 months ‒ To measure effectiveness of cocooning to prevent pertussis among infants <2 months

  10. VACCINATION RECS • DTaP is recommended for all children at 2, 4, 6 and 15–18 months of age, • with a pre-school booster between 4 years of age and entry into kindergarten. • Current ACIP recommendations call for a once-in-a-lifetime dose of Tdap • for the groups shown below. • - Children 7–10 years of age who have not received a complete series • of DTaP • - Adolescents 11–18 years of age • - Pregnant women at ≥20 weeks’ gestation • - All non-pregnant adults • - For adolescents and adults, Tdap can replace one of the decennial Td boosters.

  11. Winnable Battles in Pertussis Encouraging improved adherence to the current schedule Vaccinate pregnant women and contacts of infants Vaccinate staff in birth and neonatal units with Tdap

  12. FOR MORE INFORMATION • • OPHDpertussis page : • http://1.usa.gov/vpdpertussis • CD Summary on pertussis: • http://public.health.oregon.gov/DiseasesConditions/CommunicableDisease/CDSummaryNewsletter/Documents/2012/ohd6108.pdf • MMWR on pertussis in Washington State: • http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6128a1.htm?s_cid=mm6128a1_w • • ACIP references on pertussis: • www.cdc.gov/vaccines/recs/acip/livemeeting-feb12.htm • • CDC’s pertussis page: • www.cdc.gov/pertussis/

More Related